Bristol-Myers Squibb Announces $15.2 Billion Partnership with China's Hengrui Pharma

What happened

Bristol-Myers Squibb announced a strategic collaboration with Jiangsu Hengrui Pharmaceuticals, one of China's largest drugmakers, on May 12, 2026. The partnership brings together 13 early-stage programs: four oncology and hematology candidates from Hengrui, four immunology assets from BMS, and five jointly discovered programs. Under the agreement, BMS will pay $600 million upfront, followed by $175 million payments on the first and second anniversaries (2027 and 2028). The total deal value could reach approximately $15.2 billion through milestone payments tied to development, regulatory approvals, and commercial achievements, plus royalties on net sales. BMS receives exclusive worldwide rights to Hengrui-originated assets outside mainland China, Hong Kong, and Macau, while Hengrui gains exclusive rights to BMS assets within those territories. Hengrui will lead early clinical development to accelerate proof-of-concept work, with options to co-develop select assets and participate in certain global commercialization activities. The transaction is subject to regulatory review and is expected to close in the third quarter of 2026.

Why it matters

This partnership represents a significant strategic move for Bristol-Myers as it seeks to replenish its pipeline and diversify risk across multiple therapeutic areas. By tapping into Hengrui's discovery engine and efficient early-stage development infrastructure, BMS aims to accelerate clinical learning and make faster portfolio decisions-critical for driving growth over the next decade. The deal structure balances upfront capital commitment with performance-based milestones, allowing BMS to manage financial risk while gaining access to potentially first-in-class or best-in-class candidates. For investors, the collaboration signals BMS's disciplined approach to external innovation and its willingness to invest in emerging markets' R&D capabilities. Hengrui's track record includes previous partnerships with Merck ($200 million) and GSK (up to $12 billion), underscoring the quality of its pipeline. The deal also provides BMS with a strategic foothold in China's rapidly growing pharmaceutical market through Hengrui's local expertise, while Hengrui gains access to BMS's global regulatory and commercialization infrastructure.

Bigger picture

The partnership reflects a broader industry trend of large biopharmaceutical companies turning to China for early-stage innovation. China has emerged as an attractive partner due to its deep pool of experimental compounds, efficient clinical development timelines, and lower development costs compared to Western markets. Hengrui Pharma, with more than 100 internally discovered drugs in clinical development and 29 marketed products in China, exemplifies the maturation of Chinese pharmaceutical R&D. Major pharma companies including GSK, Merck, and now BMS have struck significant deals with Chinese biotech firms, signaling confidence in the quality and efficiency of Chinese drug discovery platforms. For the oncology, hematology, and immunology sectors-areas with high unmet medical need and intense competition-partnerships like this enable faster proof-of-concept generation and portfolio diversification. The deal also highlights how global pharmaceutical companies are increasingly structuring partnerships with geographic rights splits, allowing both parties to maximize value in their respective markets while sharing development risk.

What to watch

Investors should monitor the timing and outcome of regulatory reviews, with deal closure expected in Q3 2026. Key milestones to track include advancement of the 13 programs through early clinical development, particularly achievement of proof-of-concept data that would trigger milestone payments. Watch for announcements regarding specific drug targets and indications, which have not yet been disclosed. The $175 million anniversary payments in 2027 and 2028 will provide near-term indicators of deal progress. Longer term, pay attention to Hengrui's exercise of co-development options and any updates on the jointly discovered programs, as these could materially expand the partnership's scope. Also monitor whether BMS pursues additional China-focused collaborations, which would signal a broader strategic shift toward Asian innovation hubs. Finally, track competitive responses from other large pharma companies seeking similar partnerships, as this could influence valuation and deal structures across the sector.